Overview

This trial is active, not recruiting.

Condition induced abortion
Treatment telephone follow-up
Sponsor University of Pittsburgh
Collaborator Anonymous
Start date February 2008
End date November 2008
Trial size 139 participants
Trial identifier NCT00619658, PRO07080379

Summary

To assess the feasibility of using simplified telephone follow-up to predict pregnancy expulsion after medical abortion, and if in-person follow-up is required to determine the percentage of women that will present for that follow-up.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
telephone follow-up
subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.

Primary Outcomes

Measure
To determine the rate of completion of telephone interviews after medical abortion, and the rate of return for follow-up if necessary.
time frame: four months

Secondary Outcomes

Measure
To determine if a standardized set of questions can predict pregnancy expulsion, and to determine which method of misoprostol administration women prefer.
time frame: four months

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: - healthy females - requesting an elective termination of pregnancy by medical abortion - an intrauterine pregnancy

Additional Information

Official title The Feasibility of Simplified Telephone Follow-up After Medical Abortion
Principal investigator Lisa K Perriera, MD
Description This is a prospective trial to evaluate the feasibility of performing a telephone interview to predict if pregnancy expulsion has occurred. In those women for whom expulsion has not been predicted to have occurred, the trial will evaluate if they will present for a follow-up visit. We plan to recruit 154 women that desire a medical abortion from Magee-Womens Hospital, Planned Parenthood of Western Pennsylvania, and private offices in the surrounding area. Women who are no more than 63 days gestation will receive mifepristone 200mg and misoprostol 800mcg. Each subject will choose between two evidence-based methods of using the misoprostol: buccally 24-72 hours or vaginally 0-72 hours after mifepristone. A follow-up phone call with a clinician will occur 5-9 days after mifepristone administration. Based on clinical history, including a structured question set, the subject and the clinician will predict if expulsion occurred. If either or both feel that expulsion may not have occurred, the women will return for follow-up in the office within one week for sonographic evaluation. If they both predict that expulsion has occurred at this initial phone call follow-up, the subject will perform a urine pregnancy test at home in approximately 3 weeks. She will have a follow-up phone call after the pregnancy test to obtain the results. The subject will only have an additional visit and ultrasound examination if the urine pregnancy test is positive. The primary outcome is the percentage of women that will be available for follow-up over the phone, and/or return visit if necessary. The secondary outcomes are to determine if a standardized set of questions of clinical history after medical abortion will be useful to predict expulsion of the pregnancy and which mode of misoprostol administration women prefer. In addition, the study will confirm if women and clinicians are accurate at predicting expulsion of the pregnancy, compare the ability of patients and clinicians to predict expulsion of the pregnancy, determine how many women require follow-up evaluation after a telephone interview, and to determine the pregnancy continuation rate after misoprostol and mifepristone in this study.
Trial information was received from ClinicalTrials.gov and was last updated in October 2008.
Information provided to ClinicalTrials.gov by University of Pittsburgh.